EUVIMEDOpdag EUVIMED
Crossref

An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting

Gerald M Cherf, Robert B Lee, Nishant Mehta, Claire Clifford, Kathleen Torres, James R Kintzing, Jennifer R Cochran iD

Biotechnology and Bioengineering · 2024

DOI: 10.1002/bit.28790 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2024. Written by Gerald M Cherf and 6 co-authors. Institution: Department of Bioengineering, Stanford University, Stanford, California, USA. Major MEDLINE topics: Receptors, Urokinase Plasminogen Activator. Cited 1 times so far (Crossref); 60 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Urokinase‐type plasminogen activator receptor (uPAR) is overexpressed on tumor cells in multiple types of cancer and contributes to disease progression and metastasis. In this work, we engineered a novel bi‐paratopic uPAR targeting agent by fusing the binding domains of two native uPAR ligands: uPA and vitronectin, with a flexible peptide linker. The linker length was optimized to facilitate simultaneous engagement of both domains to their adjacent epitopes on uPAR, resulting in a high affinity and avid binding interaction. Furthermore, the individual domains were affinity‐matured using yeast surface display and directed evolution, resulting in a bi‐paratopic protein with affinity in the picomolar to femtomolar range. This engineered uPAR targeting agent demonstrated significantly enhanced tumor localization in mouse tumor models compared to the native uPAR ligand and warrants further investigation as a diagnostic and therapeutic agent for cancer.

Subjects

MeSH terms (MEDLINE)

Receptors, Urokinase Plasminogen ActivatorAnimalsMiceHumansProtein EngineeringUrokinase-Type Plasminogen ActivatorCell Line, TumorNeoplasmsVitronectinRecombinant Fusion Proteins

Author keywords

Fc‐fusionbi‐paratopic ligandprotein engineeringtumor targetingurokinase‐type plasminogen activator receptoryeast surface display

Substances

Receptors, Urokinase Plasminogen ActivatorUrokinase-Type Plasminogen ActivatorVitronectinRecombinant Fusion Proteins

Authors and institutions

  • Department of Bioengineering, Stanford University, Stanford, California, USA.
  • Department of Chemical Engineering, Stanford University, Stanford, California, USA.
  • Stanford Cancer Institute, Stanford University, Stanford, California, USA.

ORCID profiles: Jennifer R Cochran

Cite

APA

Cherf, G. M., Lee, R. B., Mehta, N., Clifford, C., Torres, K., Kintzing, J. R., & Cochran, J. R. (2024). An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28790

Vancouver

Cherf GM, Lee RB, Mehta N, Clifford C, Torres K, Kintzing JR, et al. An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28790

BibTeX
@article{Cherf2024,
  author = {Cherf, Gerald M and Lee, Robert B and Mehta, Nishant and Clifford, Claire and Torres, Kathleen and Kintzing, James R and Cochran, Jennifer R},
  title = {An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting},
  journal = {Biotechnology and Bioengineering},
  year = {2024},
  doi = {10.1002/bit.28790}
}
Start for free →